In an interview to CNBC-TV18, Rajesh Agrawal, CFO of Gulshan Polyols spoke about the latest happenings in the company and his outlook going ahead.
In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.
CNBC-TV18 learns that Sun Pharma survives 'tax evasion' charge on intellectual property rights (IPR) transfer to foreign arm.
Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.
The goods and services tax (GST) bill is an extremely positive step for both the Indian industry and consumer as it will facilitate the long term economic growth in the country, says Dilip Sanghvi, CMD of Sun Pharma.
ITI Reinsurance, a subsidiary of Fortune Financial Services, may get IRDA nod by September. It will start with Rs 500 crore initial cap, learns CNBC-TV18.
Hellen De Kloet, Biz Head-Western Europe & ANZ, Sun Pharma said the launch of â€˜Gemcitabine InfuSMART‘ will start in the UK and the Netherlands because these are the first two countries in Europe where we have final approval.
â€œRegulatory risks are waning in the sector,â€ says Abhishek Sharma, pharma analyst at IIFL. Hereon, things are expected to move in positive direction for companies.
Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.
Sun Pharma has completed a 12 weeks trial of its psoriasis drug, MK 3222, but needs 52-124 weeks data to apply for a license with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
Cipa will help in treating about 7.5-34 million people, the number of cases reported for dengue, says Kirti Ganorkar, Senior VP - Business Development & Portfolio Management at Sun Pharma.
The project will first be launched in malaria-ridden district of Mandla in Madhya Pradesh, says Altaf Lal, Senior Advisor, Global Health & Innovation at Sun Pharma.
In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.
In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.
Surya Narayan Patra of Phillipcapital says the news on Elepsia is more relevant to Sun Pharma. The product was linked to one of the facilities linked to USFDA issues
Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.
The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.
With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion
The transaction is expected to close by August 2015.
The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.
Sajjan Jindal, Chairman & MD, JSW Steel says with iron-ore and mining ordinances, it has become very clear that now it will be through the auction route, through a transparent route. So, I think over the next two years, all these large projects which are mineral based will get sorted out.
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.
The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.
Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma cautioned that the jump in operating margin to 44 percent seen during the quarter may not be sustained.